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chemotherapy had lower distant and abdominal relapse rates, 
and significantly better DFS versus those who received six cycles 
of chemotherapy and no adjuvant RT. Post-operative RT should 
be considered in the treatment regimen for this patient group.  
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Purpose: Most women with cervical cancer in Sub-Saharan Africa 
present with locally advanced disease. These women require 
external beam radiotherapy (EBRT) and brachytherapy for a 
curative treatment course. Data on the outcomes of these 
patients remain sparse. We report the experience of The 
National Centre for Radiotherapy and Nuclear Medicine in Accra, 
Ghana. 
Methods and Materials: The charts of patients treated from 
2006-2011 were reviewed. Patients treated without 
brachytherapy or with palliative intent were excluded. Staging 
CT scans were not routinely performed. Cobalt-60 EBRT was 
followed by one or two low-dose-rate brachytherapy insertions. 
Concurrent weekly cisplatin was recommended. Because many 
patients experienced delays from diagnosis to treatment, we 
calculated rates of locoregional recurrence (LRR), and distant 
recurrence (DR) from the date of the last radiation treatment to 
the event date, or last follow up, when no event recurred, using 
a competing risk approach. Overall survival was calculated from 
the date of diagnosis using the Kaplan-Meier method. 
Results: Two hundred and fifty-four patients had a median age 
at diagnosis of 55 years. FIGO stage was IB in 7% of patients, IIA 
in 13%, IIB in 43%, IIIA in 8%, IIIB in 25% (48% had sidewall 
involvement, 33% hydronephrosis, and 18% both), and IVA in 4%. 
Median dose to point A was 83 Gy (range 56-98 Gy) with a median 
contributing EBRT and brachytherapy dose of 46 Gy (range: 32-
52 Gy) and 29 Gy (range: 8-50 Gy), respectively. EBRT boosts to 
the sidewall or primary tumour were used in 12% of patients with 
a mean dose of 9 Gy (range: 4-20 Gy). Median doses to the ICRU 
bladder and rectal points were 71 Gy and 65 Gy. Sixty-four 
percent of patients received concurrent cisplatin. The median 
number of cycles was four, with 89% and 39% of patients 
receiving at least three and five cycles, respectively. Median 
overall treatment time was 73 days (range: 27-329 days). Median 
follow up was 2.5 years with many patients lost to follow up. 
Three-year OS, LRR, and DR were 87%, 20%, and 11%, 
respectively. The most commonly reported late side-effect was 
vaginal stenosis/shortening in 32% of patients. We also identified 
nearly 300 patients who were offered curative treatment but 
never returned to start; they will be the subjects of a subsequent 
study on barriers of care. 
Conclusions: We report the largest single institution series of 
cervical cancer patients treated with definitive EBRT and 
brachytherapy in Sub-Saharan Africa. Despite advanced stage at 
presentation, preliminary data is promising. However, many 
patients eligible for curative radiotherapy do not undergo 
treatment. 
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Background: Close resection margins (CM) and lymph node 
involvement with extracapsular extension (ECE) are associated 
with poor clinical outcome of patients with squamous cell head 
and neck cancer (SCCHNC) after surgical resection and adjuvant 
chemoradiation. We performed in this subset of patients an open 
label Phase 2 trial and investigated the effect of additional 
cetuximab administered concomitantly and as maintenance 
therapy during and after adjuvant radiochemotherapy. 
Methods and Materials: Surgically treated SCCHNC with CM or 
ECE were eligible for the study. 61.6 Gy (1.8/2.0/2.2 Gy, d1-36) 
were administered using an integrated boost IMRT-technique. 
Cisplatin (20 mg/m2, d1-5 and d29-33) and 5-FU (continuous 
infusion: 600 mg/m2, d1-d5 + d29-33) were given concurrently. 
Cetuximab started seven days prior to radiochemotherapy at 400 
mg/m2 followed by weekly doses of 250 mg/m2. Maintenance 
cetuximab began after radiochemotherapy at 500 mg/m² every 
two weeks for six months. The study was conducted at 10 
investigational sites recruiting in Germany from May 2008 until 
December 2010.  
Results: The number of patients enrolled was 83. Five patients 
did not meet inclusion criteria leaving 78 for analysis. Median 
follow up of was1.5 years. Eighteen patients had events (death 
of progression) of which 10 were locoregional relapses. Two-year 
overall survival, disease-free survival, and locoregional tumour 
control were 86% (95%CL 79-95%), 77% (95% CL 66-86%), and 82% 
(95%CL 93-78%). Acute toxicity was in the expected range 
(separate abstract). Two thirds of patients started maintenance 
cetuximab after completion of chemoradiation and on third 
completed all treatment as scheduled. 
Conclusions: Adjuvant radiochemotherapy with concomitant and 
maintenance cetuximab is feasible and results in a favourable 
clinical outcome in high-risk SCCHNC after surgical resection 
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Purpose: The causal relationship between cancer of the cervix 
uteri and infection with human papillomavirus (HPV) has been 
adequately studied. There are also indications that there is a link 
between HPV infection and squamous cell carcinoma of the head 
and neck. The aim of this study was to find out the incidence and 
clinical outcome of HPV infection in head neck cancer patients 
in a German population. 
Methods and Materials: In a retrospective study, the tumour 
tissue from 164 patients (110 men, 54 women, 62.8 years + 12.7) 
with head neck cancer (oropharynx = 65 nasopharynx = 10, larynx 
= 13, hypopharynx = 15, oral cavity = 33 CUP = five, Other = 23) 
were tested for HPV infection and the clinical outcome was 
investigated. p16 as a surrogate marker for HPV infection was 
determined. Moreover, risk factors such as nicotine, alcohol 
abuse, resection margin of the tumour tissue, histology, lymph 
nodes involvement, extracapsular spread, tumour stage, and the 
treatment of the tumour were analyzed for local control and 
overall survival. 
Results: The incidence of HPV infection in oropharynx-carcinoma 
patients was 33%. Patients with HPV-positive oropharyngeal 
carcinomas showed a tendency towards longer survival time, (p 
= 0.76, HR: 2.42, 95% CI 0.91 - 6.44) compared to HPV-negative 
tumours. All other parameters were except the tumour stage in 
the uni and multivariate analysis not significant for local control 
and overall survival. The reason for this might be the small 
number of cases in our individual subgroups 
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Conclusions: The HPV infection in Germany was lower than 
expected. Also in our investigation it appears that HPV positive 
patients have a better clinical outcome than HPV negative 
patients. 
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Introduction: Sinonasal undifferentiated carcinoma (SNUC) is a 
rare aggressive neoplasm arising in the nasal cavity and paranasal 
sinuses. Although intracranial extension from SNUC is common in 
patients with locally advance disease, distant central nervous 
system metastasis from SNUC is an extremely rare occurrence.  
Methods and Materials:  Herein, we present a case, and review 
the limited literature on overall management and outcomes of 
patients with SNUC and management and outcomes of patients 
with SNUC with brain metastases. 
Results:  We report a case of an 80 year old man who presented 
with a locally advanced SNUC involving ethmoid, sphenoid and 
maxillary sinuses and bilateral lymph nodes from level I-V, 
cT4N2cM0. Given his age and the initial extent of his primary 
tumour, he was treated with neo-adjuvant chemotherapy 
followed by palliative chemoradiation with a split course of 50 
Gy in 40 fractions delivered twice a day. Four months after his 
treatments, he developed a recurrence at the left lower eyelid 
and left frontal sinus, intra-abdominal metastases and a left 
cerebellar metastasis. A single fraction of 22 Gy was delivered to 
the cerebellar lesion using stereotactic radiosurgery.  
Upon review of the literature, we found only two cases reported 
of brain metastases that were not due to local intracranial 
extension from the original mass, in which detailed treatment 
information was reported. One patient with partially controlled 
local disease had a left temporoparietal lesion treated with a 
combination of bone marrow transplant and CAV chemotherapy 
and had a partial response. This patient died of disease at 8 
months. The second case was treated initially with surgical 
resection and post-operative chemotherapy and radiation and 
lived for at least another two years while developing further 
metastases- at the time of the printed manuscript the patient 
was still alive.  
Conclusions:  We advocate that aggressive treatment of 
advanced SNUC may be pursued in selected patients. We suggest 
a registry for rare head and neck cancers such as SNUC to help 
guide treatment. 
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Purpose: Stereotactic body radiation therapy (SBRT) has become 
the standard therapy for inoperable early stage non-small cell 
lung cancer (NSCLC) and is increasingly more accepted as an 
alternative to surgery in operable patients. Despite the 
widespread use of SBRT in early stage NSCLC, the ideal dose 
fractionation for treating peripheral lesions is yet to be 
identified. Our institution has pioneered the use of 48 Gy in 3 
fractions as an SBRT dose fractionation schedule. We sought to 
evaluate the efficacy and toxicity associated with this regimen, 
in comparison to outcomes of patients treated at our institution 
with other commonly used SBRT dose regimens.  
Methods and Materials: We retrospectively reviewed the 
medical charts and radiation oncology records of consecutive 
patient with inoperable early stage NSCLC (T1-2 N0 M0) treated 
with SBRT at our institution between May 2010 and March 2015. 
Demographic patient data and dosimetric data regarding SBRT 
treatments were collected. Local/regional control, distant 
failure and overall survival were analyzed. Acute toxicity 
(defined as toxicity<90 days) and late toxicity (defined as 
toxicity>= 90 days) were also reported and graded as per 
standardized Common Terminology Criteria for Adverse Events 
(CTCAE) v4.0. 
Results: A total of 179 consecutive patients with a median age 
of 74.5 years were included. Ninety-eight patients with 110 
lesions received an SBRT dose of 48 Gy in 3 fractions over 5 - 7 
days (Group 1). Eighty one patients with 86 lesions (Group 2) 
received other standard SBRT fractionation schemes (25- 60 Gy 
in 1 – 5 fractions). After a median follow of 20 months (range 6 – 
95), 63% of patients treated with 48 Gy in 3 were alive. The crude 
rates of local, regional and distant failures in groups 1 and 2 were 
12.7%, 9.1%, 15.5% and 22.1%, 17.4% and 23.5%, respectively. 
The odds ratio for local failure, regional failure and distant 
metastasis were 0.5, 0.5 and 0.6 respectively in favour of the 48 
Gy in 3 dose fractionation. There were no cases of SBRT related 
Grade 3 or higher acute or late toxicity.  
Conclusions: The use of SBRT 48 Gy in 3 fractions for peripheral 
early stage NSCLC is associated with excellent outcomes and 
compare favourably with published results of 54 Gy in 3 fractions, 
and 48 Gy in 4 fractions. The favourable toxicity profile 
associated with using 48 Gy in 3 fractions highlights this regimen 
as safe and convenient option for the treatment of peripheral 
lesions in close proximity to the chest wall.  
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Purpose: Lung cancer is the leading cause of cancer-specific 
mortality in North America. Main reason for the high mortality is 
the advanced stage at diagnosis in the majority of patients. Early 
detection of lung cancer by screening high-risk individuals has 
been proposed to improve survival. An effective screening 
program may prevent up to 80% of the deaths from lung cancer. 
We undertook this study to determine if 1H Magnetic Resonance 
Spectroscopy (MRS) of sputum and exhaled breath condensate 
samples can complement and or provide an alternate tool to 
screen and detect lung cancer among high-risk population. 
Methods and Materials: Sputum and Exhaled Breath Condensate 
(EBC) samples were collected from 15 patients. Pathologically 
confirmed non-small cell lung cancer (NSCLC, n = 8), and patients 
with respiratory conditions other than lung cancer (controls, n = 
7) were enrolled. Both sputum and EBC samples were collected 
in thirteen patients; two patients provided EBC samples only. 
Sputum samples were thawed and 250 mL of each sample was 
dispersed in 2M NaCl (prepared in PBS buffer) solution in the ratio 
1:1 (v/v) and vortexed to get homogenous clear suspension; 
frozen EBC samples were thawed and 500 mL neat sample was 
transferred into the NMR tube (with a reusable co-axial capillary 
tube containing standard TSP solution in D2O) for analysis. All 
MRS experiments were performed on a Bruker Avance 400 MHz 
NMR spectrometer at the University of Winnipeg. In order to 
detect metabolite signals, the water signals in both EBC and 
sputum samples were suppressed using PRESAT or excitation 
sculpting pulse sequence. The MRS lab staff was blind to the 
diagnosis until all the samples were analyzed. 
Results: In EBC samples, propionate was detected in 43% of the 
patients in both groups; with similar median concentration of the 
metabolite. Ethanol and acetate were detected in all patients, 
with relatively higher median concentration of the metabolites 
in the cancer group. Acetone and formate were detected in 75% 
and 50% of the cancer group and 43% and 57% of the control 
group, with higher median concentration of the metabolites in 
cancer group. Methanol was detected in 75% and 100% of the 
cancer and control group respectively, with median lower 
